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WƌŽĨŝůŝŶŐƉƐǇĐŚŽƚƌŽƉŝĐĚŝƐĐŚĂƌŐĞŵĞĚŝĐĂƚŝŽŶĨƌŽŵĂĐŚŝůĚƌĞŶ ?ƐƉƐǇĐŚŝĂƚƌŝĐǁĂƌĚ 
Background: Psychotropic medication is increasingly used in children to treat psychiatric symptoms or 
illnessess [1] and behaviours associated with autistic spectrum disorders [2].  Child and adolescent 
psychiatrists report that stimulants or antipsychotics, namely the atypical antipsychotics, are the 
medicines they use most frequently in this population [3]. However, the majority of prevalence studies 
tend to be based upon community or outpatient populations. Information about psychotropic 
medication use ŝŶĐŚŝůĚƌĞŶ ?Ɛin-patient psychiatric services is largely non-existent.  In the UK, there are 
eight NHS inpatient psychiatric units for children aged 12 years and younger.  The units tend to be 
small (6-10 beds) with an average length of stay of 116 days [4].  Despite the controversial nature of 
admitting children with mental health issues to in-patient units, they can have a positive impact 
compared to outpatient interventions, particularly in life threatening situations e.g severe depression, 
eating disorders [4].  Much of the pharmacological treatment of childhood psychiatric conditions is 
based upon knowledge and experience of the medication in adult populations.  Prescribing governance 
for psychotropic medication use in children is often limited and much of the medication is used in an 
ƵŶůŝĐĞŶƐĞĚŽƌ ?ŽĨĨůĂďĞů ?ŵĂŶŶĞƌ [5].  This includes using licensed medicines for unlicensed indications 
e.g clonidine for treatment of Attention Deficit Hyperactivity Disorder [ADHD] or using unlicensed 
doses.  By characterising the nature of psychotropic medication used in one ĐŚŝůĚƌĞŶ ?ƐƉƐychiatric unit, 
this paper intends to inform prescribing practice within this highly specialised area.   
Objective: To characterise the nature of psychotropic medication prescribed on discharge from a 
ĐŚŝůĚƌĞŶ ?ƐƉƐǇĐŚŝĂƚƌŝĐunit over a 15 year period.  
Method: A retrospective analysis of discharge summary letters for all children discharged from a 
psychiatric unit between Jan 1997 to December 2012.  Anonymous demographic and discharge 
medication details were extracted. Only medication prescribed for treatment of a psychiatric 
condition, including emotional or behavioural symptoms and treatment of neuro-developmental 
disorders including tics was included.  Medication for seizure control was excluded.  Non-psychotropic 
medicines were included if they were used for psychiatric reasons.  Other ĚĞƚĂŝůƐ ?ĐŽŶĐĞƌŶŝŶŐĚŽƐĂŐĞƐ
and indication, where available was also extracted.  Ethical approval was not required as the study 
involved analysis of routinely collected prescribing data and was therefore considered as service 
evaluation.   
 
Results: 
Patient population 
234 children [152 males (65%) & 82 females] were admitted over the study period with a mean of 15 
admissions per year.  The mean age on admission was 9 years, 7 months (range 4 - 14yrs).  117 patients 
(50%) were prescribed psychotropic medication on discharge, including 24 (n=19 males) who were 
discharged on more than one psychotropic medicine.  Overall, 133 medicines were prescribed at 
discharge. These consisted of; stimulants (immediate Release n=35, sustained Release n=14), 
antipsychotics (atypical n=23, typical n= 8), antidepressants (SSRIs n=15, other n=7), other medication 
used for ADHD (n=11), melatonin (n=10), benzodiazepines (n=7), sodium valproate (n=1)  and other 
medications (hyoscine n=1 and alimemazine n=1).   
 
x Antipsychotics 
31 patients (26%) were discharged on an antipsychotic.  The majority were male (n= 21, 68%) with a 
mean age of 11 yrs.  Risperidone was most frequently prescribed (n=14) at a mean daily dose of 1mg 
(range 0.25  ? 4 mg, based upon 14 patients).  As the number of children discharged on an antipsychotic 
was relatively small every year; further analysis to find trends/rates in prescribing was not possible.  
x Stimulants and other ADHD medication 
55 patients (47%) were discharged on a stimulant or another medication used for treating the 
symptoms of ADHD. 96% (n=53) were male with a mean age of 10 yrs.  Some individuals were 
prescribed combinations of immediate and sustained release methylphenidate (MPH) (n=42); 
methylphenidate or dexamfetamine augmented with either atomoxetine (n=6) or clonidine (n=6). 
Further analysis to determine trends in the rate of prescribing was not performed.  
x Unlicensed Use 
59 patients (50% of all patients discharged on medication, 25% of the total sample) were given an 
unlicensed medicine or a licensed drug was used in an unlicensed manner.  (See Table 1).  Risperidone 
was the most common drug to be used in this manner (n=14).  Sleep disturbance and tics were the 
most common diagnosis to be treated using unlicensed/off label medication (n=10).  
 
Discussion: 
Fifty per cent of children discharged from the unit were prescribed a psychotropic medication, of which 
stimulants were the most popular.  This does not mean that all discharges had a definitive diagnosis of 
ADHD- but rather elements of inattention, hyperactivity or impulsivity were apparent and treated as 
such.  Movement and autistic spectrum disorders were also common amongst this cohort and widely 
recognised as occurring alongside ADHD.  For example, 60- ? ?A?ŽĨĐŚŝůĚƌĞŶǁŝƚŚ,ŚĂǀĞdŽƵƌĞƚƚĞ ?Ɛ
ƐǇŶĚƌŽŵĞ  ? ? ? ? dŚŝƐ ŽĨƚĞŶ ƌĞƐƵůƚƐ ŝŶ  ?, ŵĞĚŝĐĂƚŝŽŶ ?ďĞŝŶŐ ƵƐĞĚ ŝŶ ĂŶ ƵŶůŝĐĞŶƐĞĚ ŵĂŶŶĞƌ Ğ ?Ő 
atomoxetine for attentional/hyperactivity symptoms in patients on the autistic spectrum or with 
dŽƵƌĞƚƚĞ ?Ɛ ƐǇŶĚƌŽŵe.  Similarly, methylphenidate for ADHD may be used alongside behavioural co-
morbidites and at higher than licensed doses e.g 72 mg daily.  Clonidine, licensed for hypertension is 
also effective in ADHD with the unlicensed use of clonidine specifically referred to in the NICE ADHD 
guidelines [7]. 
 
Melatonin is a recognised treatment for sleep disorders in children and widely prescribed at discharge.  
However, there are no licensed preparations in the UK for children.  Generally, prescribers use the 
Circadian® brand  but  in an off license manner or the Bio-Melatonin brand which has an EU but not a 
UK license.   The majority of unlicensed medication use on this unit occurs with the antipsychotics, 
particularly risperidone.  Most prescribed doses for risperidone were within the licensed dosage range 
for treatment of persistent /severe aggression in children with conduct disorder.  However, its use is 
ƵŶůŝŬĞůǇ ƚŽ ďĞ ƌĞƐƚƌŝĐƚĞĚ ƚŽ Ă  ?ĐŽŶĚƵĐƚ ĚŝƐŽƌĚĞƌĞĚ ? ƉŽƉƵůĂƚŝŽŶ ? Regardless of the complexities of 
specific diagnosis and associated symptoms, risperidone is effective against aggression and irritability, 
which explains its use amongst children with ASD, anxiety and ADHD, all of which exhibit elements of 
aggression and irritability, ƐŽŵĞƚŝŵĞƐ ĐĂůůĞĚ  ?challengŝŶŐ ďĞŚĂǀŝŽƵƌ ? ?   dŚŝƐ ŝƐsimilar to the situation 
found in the elderly where antipsychotics have been used to address  ?behaviours associated with 
dementia ?.  The atypical antipsychotics were initially perceived to have a better side effect profile than 
the older typical antipsychotics.  However, complications arising from weight gain, metabolic syndrome 
and hyper-prolactinaemia caused by the atypicals have curbed initial enthusiasm [8].  In adults, regular 
monitoring of physical parameters (LFTs, U&Es, fasting plasma glucose, HbA1Cetc) is recommended and 
should occur at the start of treatment and at subsequent dosage increases [9].  In children, particularly 
those with mental health issues, such monitoring poses its own set of difficulties.  Children unaware of 
the implications can be reluctant or totally refuse to permit any type of blood-letting.  This often 
results in treatment being initiated and given without the recommended baseline or subsequent 
clinical parameters being established.   Monitoring if it occurs tends not to be in accordance with 
recommended guidance (albeit for a different population).  Nevertheless, despite the wide range of 
uses for antipsychotics in children, there is a dearth of information about their clinical effectiveness 
and long-term safety within this age-group, particularly when co-prescribed with other psychotropic 
medicines.   
 
It is unfortunate that patient turnover and hence discharges from the unit were relatively modest. This 
is partly indicative of mental health services in general, where inpatient stays tend to be for a longer 
period.  Additionally, given the added complexity of co-ŽƌĚŝŶĂƚŝŶŐĐĂƌĞǁŝƚŚŽƚŚĞƌ ?ĐŚŝůĚƌĞŶ ?Ɛ ?ƐĞƌǀŝĐĞƐ
upon discharge, inpatient stays for children can become rather protracted.  This partly explains the low 
average number of discharges (15 per year) seen in this study.  The small number of children 
discharged on antipsychotics each year, made it difficult to analyse the data in a longitudinal manner.  
However, it is clear that a range of antipsychotics, including the older typical drugs have been in use 
over the past 15 years.  The arrival of the atypical antipsychotics is thought to be a contributing factor 
to the increased use seen in the community.  It is unknown whether this has been a factor in unit 
prescribing.  
 
Unlike adult services where psychotropic medication is prescribed to many patients at discharge, only 
half of those discharged from this unit were prescribed psychotropic medication.  One reason could be 
that since the majority of cases had elements of anxiety associated with them, and psychological 
treatment is the preferred option for these [10], the low number indicates that psychological therapies 
are being   ?ƉƌĞƐĐƌŝďĞĚ ?instead of medication.  This would need to be further investigated.  
Alternatively, perhaps clinicians, wary of the limited knowledge concerning long term use of 
psychotropic medication on the developing brain, are choosing to time limit the duration that such  
medication is being taken by their patients.   
 
This study describes the nature of psychotropic medication prescribed on discharge from a specialist 
inpatient unit and cannot be generalised to patterns of prescribing seen in community paediatric 
populations receiving psychiatric care. 
 
Conclusion: Stimulants and atypical antipsychotics are the most commonly prescribed drugs on 
ĚŝƐĐŚĂƌŐĞ ĨƌŽŵ Ă ĐŚŝůĚƌĞŶ ?Ɛ ƉƐǇĐŚŝĂƚƌŝĐ ǁĂƌĚ ?  DƵĐŚ ŽĨ ƚŚĞ ĂŶƚŝƉƐǇĐŚŽƚŝĐ ƵƐĞ ŝƐ ĨŽƌ unlicensed 
indications or at unlicensed doses.   
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Table 1.  Details of discharge medication when used in an unlicensed manner 
Drug Name, licensed indication and max 
daily dose in children  where indicated (as 
per BNF for Children or SPC) 
Off label use in children* Indication and Dosage  n = 59 
Clozapine  n=1 
x Unlicensed in children  
x Schizophrenia 
(adult max 900mg daily) 
1 X early onset schizophrenia, 62.5mg bd 
Haloperidol (oral)  n=2 
x Childhood behavioural disorders  
associated with hyperactivity & 
aggression (max 3mg daily) 
x Childhood schizophrenia (max 6mg daily) 
x Tourette syndrome (max 3mg daily) 
x Tics 
x Tourette syndrome 
 
2 X Tics, 0.5mg & 6mg daily 
Risperidone (oral)  n=14 
x Short term treatment of persistent 
/severe aggression in conduct disorder 
or autism >5yrs   (max 1mg  ? 3mg daily) 
x Anxiety 
x Compulsivity/Rigid thinking associated with 
autism 
x Tics 
x Psychosis 
5 X Tic disorder, doses range from 0.2mg - 1.0mg daily 
9 X Psychosis / delusional/rigid thinking associated with 
Autistic Spectrum Disorder, doses range from 0.5mg  ? 1.5mg 
daily 
 
Quetiapine  n=1 
x Unlicensed in children 
 
x Psychosis 
x Schizophrenia (max 750mg daily) 
x Mania (max 600mg daily) 
1 X Unspecified non-organic psychosis , 400mg bd 
 
Sulpiride  n=4 
x Unlicensed in children 
x Psychosis (max 800mg daily 
x Tourette syndrome (max 800mg daily) 
3 X Psychosis, doses range from 100mg - 300mg daily   
1 x Tourette Syndrome, dosage information missing 
Atomoxetine  n=2 
x ADHD  (max 120mg daily) 
 
x Impulsivity  
x Motor hyperactivity associated with autism 
x Tics 
2 X Aspergers syndrome & impulsivity, 25  & 50mg daily 
 
Methylphenidate SR (Concerta) n=2 
x ADHD (max dose 54mg) 
x Impulsivity 
x Motor hyperactivity 7 inattention  
associated with autism 
2 X ADHD: 2 X Unlicensed dose of 72mg mane 
lisdexamfetamine  n=1 
x ADHD (max dose 20mg) 
x Unknown Imported from US as Vyvanse- used prior to granting of UK 
license,  30mg mane 
Clonidine  n=6 
x Severe hypertension (max 1.2mg daily) 
x ADHD  
x Tic disorders  (max 0.4 mg daily) 
2 X ADHD, 50mcg & 100mcg daily 
2 X Tics / Tourette syndrome, 50mcg & 150mcg daily 
2 
 
x Agitation 
x Aggression 
x Hyper arousal  (max 0.4mg daily) 
2 X Aggression associated with Autistic Spectrum Disorder, 2 X 
50mcg bd  
Clomipramine  n= 5 
x Unlicensed in children 
x Obsessive Compulsive Disorder (max 3-
5mg/kg daily) 
x Phobia / anxiety states 
x Depression    
4 X Obsessive Compulsive Disorder, doses range from 20mg  ? 
125 mg daily.  
Anorexia Nervosa & Depression, 40mg bd 
 
Imipramine n=1 
x Unlicensed in children 
x ADHD ADHD, dosage information missing 
Lofepramine n=1 
x Unlicensed in children 
x Depression Psychotic Depression, 105mg mane 
Sertraline  n=4 
x Obsessive Compulsive Disorder (not 
<6yrs, max 200mg daily) 
x Depression 
x Anxiety 
x Social phobia 
 
Depression , 100mg mane 
2 X Generalised Anxiety Disorder, 150mg  & 100mg mane 
Separation Anxiety Disorder, 150mg mane 
Melatonin  n=10 
x Short-term treatment of primary 
insomnia > 55 yrs. 
x Unlicensed in children 
x Disordered sleep associated with 
neurodevelopment disorders including 
ADHD & Autism 
Doses ranging from 2mg  ? 15mg nocte 
Diazepam  n=3 
x Unlicensed in children 
x Anxiety Unspecified non  ?organic psychosis, 5mg tds 
Catatonia, 2mg PRN 
Anxiety , 3mg nocte 
Lorazepam n=1 
x Unlicensed in children 
x Anxiety 
x Catatonia 
Anxiety, 1mg tds 
Sodium Valproate n=1 
x Unlicensed for bipolar disorder in 
children 
x Mood Stabiliser  Bipolar Disorder,  300mg bd 
* children refers to 12 yrs and younger.  
 
